Over 115 companies, across the world, claim to offer a variety of product development <claims Roots Analysis>

Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

Key Inclusions

• A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides / proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations / certifications received (if any).
• A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
• An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.
• An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
• A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
• A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.

 

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

The USD 9.3 billion (by 2030) financial opportunity within the microbial biomanufacturing market has been analyzed across the following segments:

• Type of Product
• API
• FDF

 

• Type of Biologic

• Proteins
• Enzymes
• Growth Hormones
• Antibody based Drugs
• Others (plasmid DNA, probiotics, microbiome-based biologics)

 

• Type of Microbial Expression System

• Bacteria
• Yeast
• Others (Algae and fungi)

 

• Scale of Operation
• Commercial
• Preclinical / Clinical

 

• Type of End User
• Small Companies
• Mid-sized Companies
• Large / Very Large Companies

 

• Key Geographical Regions
• North America
• Europe
• Asia Pacific
• Middle East and North Africa
• Latin America

 

The Microbial Contract Biomanufacturing Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

• AGC Biologics
• Aldevron
• BioVectra
• EirGenix
• Etinpro
• Eurogentec
• Northway Biotechpharma
• Ology Bioservices
• Porton Biopharma
• Stelis Biopharma

 

Table of Contents

 

1. Preface

2. Executive Summary

3. Introduction
 

4. Market Landscape
 

5. Company Competitiveness Analysis

 

6. Company Profiles
 

7. Recent Partnerships
 

8.  Recent Expansions
 

9. Microbial fermentation technology platforms
 

10. Assessment of Relative Competition and Growth
 

11. Make versus Buy Decision Making Framework

 

12. Big Pharma Initiatives in Microbial Biomanufacturing

 

13. Case study: comparison of small molecule and large

 

14. Market Sizing and Opportunity Analysis
 

15. Impact of covid-19 pandemic on microbial contract biomanufacturing market

 

16. Swot Analysis

 

17. Conclusion Appendix 3: List of Companies and Organizations

18. Interview Transcripts

 

19. Appendix 1: Tabulated Data

 

20. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]